Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.

The Israeli firm’s gene therapy asset has disappointed in an advanced ovarian cancer study, leaving experts skeptical of its potential in other tumors and the company turning to an earlier program.

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.